`
`
`
`NOTE: This order is nonprecedential.
`
`United States Court of Appeals
`for the Federal Circuit
`______________________
`
`SANOFI-AVENTIS U.S. LLC, SANOFI-AVENTIS
`DEUTSCHLAND GMBH, SANOFI WINTHROP
`INDUSTRIE,
`Plaintiffs-Appellants
`
`v.
`
`MYLAN GMBH, BIOCON LTD., BIOCON
`RESEARCH LTD., BIOCON SDN.BHD, BIOCON
`S.A.,
`Defendants-Appellees
`______________________
`
`2021-1262
`______________________
`
`Appeal from the United States District Court for the
`District of New Jersey in No. 2:17-cv-09105-SRC-CLW,
`Judge Stanley R. Chesler.
`______________________
`
`SUA SPONTE
`______________________
`
`Before DYK, CLEVENGER, and TARANTO, Circuit Judges.
`PER CURIAM.
`
`O R D E R
`
`
`
`
`
`Case: 21-1262 Document: 64 Page: 2 Filed: 12/29/2021
`
`2
`
`
`
`SANOFI-AVENTIS U.S. LLC v. MYLAN GMBH
`
`Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland
`GmbH, Sanofi Winthrop Industrie (collectively, “Sanofi”)
`filed a patent infringement suit against Mylan GmbH, Bi-
`ocon Ltd., Biocon Research Ltd., Biocon Sdn.Bhd., and Bi-
`ocon S.A. (collectively, “Mylan”) in the District Court for
`the District of New Jersey asserting Mylan infringed
`claims 21, 22, 25, and 30 of Sanofi’s U.S. Patent No.
`9,526,844 (“the ’844 Patent”). The district court found no
`infringement of the asserted claims and that the asserted
`claims are invalid for lack of written description. Sanofi ap-
`peals.
`We affirmed today in a related appeal, Sanofi-Aventis
`U.S. LLC, et al. v. Mylan GmbH, et al., No. 2020-2068, the
`final written decision by the U.S. Patent Trial and Appeal
`Board in IPR2018-01680 holding that claims 21–30 of the
`’844 Patent would have been unpatentable as anticipated
`and/or obvious. Accordingly, Sanofi’s appeal from the dis-
`trict court’s ruling is moot.
`
`IT IS ORDERED THAT:
`
`Sanofi’s appeal in Appeal No. 2021-1262 is dismissed
`as moot.
`
`
`
`
`
`December 29, 2021
` Date
`
`
`
`FOR THE COURT
`
`/s/ Peter R. Marksteiner
`Peter R. Marksteiner
`Clerk of Court
`
`